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Abstract 
Objective: This systematic review aimed (i) to explore the Patient-Reported 
Outcome Measures (PROMs) currently used in the oral mucosal disease 
literature and to report on the type and context of the use of these instruments 
and (ii) to provide a future direction for PROMs in oral medicine practice and 
research. 
Study Design: A systematic review of published English-language articles 
relating to the use of PROMs in the oral mucosal diseases literature was 
performed in November 2013.  
Results: One hundred and thirty one articles met the inclusion criteria, which 
addressed the following oral mucosal conditions: 75 lichen planus; 30 
recurrent aphthous stomatitis; 14 mucous membrane pemphigoid/pemphigus 
vulgaris; 1 orofacial granulomatosis and 11 articles addressed multiple oral 
mucosal diseases. The most commonly used instruments were Visual 
Analogue Scales (VAS) and the Oral Health Impact Profile (OHIP). 
Conclusions: Limited progress has been achieved with use of PROMs in oral 
medicine in the last few decades in both clinical practice and a research 
setting. With the engagement of allied medical disciplines in PROM usage 
and the promotion of PROMs by national healthcare bodies globally, 
advancement of PROMs is imperative for oral medicine. Exposure through the 
World Workshop on Oral Medicine (WWOM), along with potential involvement 
in the Core Outcome Measures in Effectiveness Trials (COMET) or other such 
initiatives, will enable worldwide collaboration to promote the development 
and utilization of valid and reliable PROMs in oral medicine, and improve 
patient care. 
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Introduction 
A patient-reported outcome measure (PROM) is an instrument for patients to 
assess their health, without external interpretation or extrapolation1, 2. The 
outcome may represent a measure of symptoms and signs that equate with 
the state of the disease, or it may represent a change from a previous 
measure. PROMs commonly include psychosocial changes, changes in 
health status, ability to function, and satisfaction with the care provided 3, 4. 
The importance of evaluating the patients’ perceptions of the impact of their 
health on daily living has been well established 5.  Patients can provide key 
information regarding the day to day impact of the chronic diseases they 
suffer from, which can prove helpful in their healthcare 6. Studies have 
determined that PROM use in clinical practice can have a positive impact on 
communication between patients and clinicians, and can also have a positive 
impact on both diagnosis and treatment 7, 8. Outcome measures are also 
increasingly important to establish patient reported benefits9 in healthcare and 
evidence that PROMs improve patient care10  in general medicine.  
 
Some progress has been made in the use of PROMs in oral medicine from 
early studies reporting on anxiety and depression in population groups 11, 12, 
to the importance of valid and reliable instruments highlighted by Hegarty et al 
13 and the use of PROMs as outcomes in clinical trials 14. Due to the chronic 
nature of common oral medicine conditions such as orofacial pain, salivary 
dysfunction and oral mucosal lesions and an underestimation by clinicians of 
the impact of these conditions on the lives of patients 15, 16 , the use of 
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PROMs in assessing the treatment of patients with chronic oral mucosal 
diseases is of great importance.  
 
Cochrane reviews of clinical trials of oral mucosal disease (i.e. management 
of both oral lichen planus (OLP) 17, 18, mucous membrane pemphigoid (MMP) 
19, along with other reviews in the area of bullous diseases 20, 21) provide 
limited information regarding PROMs.  No overview of current PROMs usage 
in oral mucosal diseases literature has been reported.  The purpose of this 
systematic review was (i) to explore the PROMs currently used in the oral 
mucosal disease literature and to report on the type and context of the use of 
these instruments and (ii) to provide future direction for PROMs in oral 
medicine practice and research.  
 
Materials and Method 
Search Strategy 
Search strategies for this review were designed to retrieve references relating 
to the use of PROMs in the oral mucosal diseases literature.  An initial search 
was conducted using the following key terms: ‘patient centered’, ‘outcome 
measurement’, ‘patient defined’, ‘patient reported outcome’, ‘patient reported 
outcome measure’, ‘subjective outcomes’, ‘scale’, ‘score’, ‘instrument’, 
‘research instrument’, ‘questionnaire’, ‘inventory’ AND ‘oral lichen planus’, 
‘recurrent aphthous stomatitis’, ‘recurrent oral ulcers’, ‘mouth ulcers’ 
‘pemphigoid’, ‘pemphigus’, ‘orofacial granulomatosis’, ‘Melkersson Rosenthal 
Syndrome’, ‘cheilitis granulomatosa’, ‘granulomatous cheilitis’. This search, 
carried out in November 2013, was developed for MEDLINE (through 
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PubMed), and then adapted to the other databases, including EMBASE, 
CINDHL, Web of Science Citation Index and the Cochrane Database of 
Systematic Reviews.  
 
Inclusion and Exclusion Criteria  
Articles were included in the review if they fulfilled the following criteria:  
Publication in the English language, published in a peer-reviewed journal, 
inclusion of a report on the use of a PROM in patients with a specific oral 
mucosal disease as identified in our search strategy.   
 
Articles were excluded from this review if they were based solely on author 
opinion, or if they were editorials or letters.  Articles concerning the etiology, 
management or narrative reviews of oral mucosal disease were also 
excluded. 
 
Data extraction 
A specific data extraction form was constructed for this review. Each reviewer 
was calibrated with three articles, which had completed gold standard data 
extraction forms. Data items recorded included study aims and objectives; 
study type (population-based studies; questionnaire properties, development 
and validation-based studies; treatment-based studies); patient reported 
outcome measures used and study outcome. Each article was evaluated 
independently by two reviewers, with disagreements resolved by the primary 
author (RNR).   
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Results 
Search results 
The initial literature search yielded a total of 986 citations, to include 
duplicates and unrelated references. Following a review of the titles and 
abstracts, 189 abstracts were selected with 131 deemed suitable for inclusion 
in this systematic review (Table 1). These papers were then catalogued as: 
OLP studies (n=75) (Table 2), recurrent aphthous stomatitis (RAS) studies 
(n=30) (Table 3), bullous (mucous membrane pemphigoid/pemphigus vulgaris 
(MMP/PV) disease studies (n=14) (Table 4), orofacial granulomatosis (OFG) 
studies (n=1) (Table 5) and multi-disease (multi) studies (n=11) (Table 6) with 
the PROMs used. The most commonly used instruments were Visual 
Analogue Scales (VAS) and the Oral Health Impact Profile (OHIP). 
 
Of the 75 OLP articles, 47 concerned treatment interventions, 5 related to 
questionnaire validity, sensitivity and correlation to clinical scoring systems, 
and 23 studies were population based. The VAS was the most commonly 
used of the 33 various PROMs used in OLP studies.  
 
Of the 30 RAS articles, 20 were concerned with treatment interventions, one 
was related to the development of a clinical scoring system for both RAS and 
Behçet’s disease with the incorporation of patient input using a VAS to record 
pain, and nine studies were population-based measuring the psychological 
impact of the disease and the quality of life in patients with RAS. Eleven 
studies used VAS, with this instrument being the most commonly used PROM 
in RAS studies.  
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Of the 14 MMP/PV articles, four were concerned with treatment interventions, 
two were related to the development or validation of clinical scoring systems 
that included VAS, and eight studies were population based evaluating 
periodontal status, quality of life and mental health. Ten PROMs were used 
with clinical scoring systems incorporating VAS. This instrument being the 
most commonly used PROM in MMP/PV studies.  
 
Paediatric Quality of Life Inventory (PaedsQL) was used in the single OFG 
article of a patient cohort attending paediatric oral medicine clinics.  
 
Eleven articles incorporated multiple oral mucosal diseases, with one 
exploring the use of topical clobetasol propionate in the treatment of RAS and 
OLP, five were related to the development of new instruments, namely 
Chronic Oral Mucosal Diseases Questionnaire (COMDQ) and the 
Autoimmune Bullous Disease Quality of Life questionnaire (ABQOL), or the 
validation of existing PROMs, and five studies were population based. Ten 
various PROMs were used with OHIP, with this instrument being the most 
commonly used PROM in these studies.   
 
 
Discussion 
The importance of patient involvement in their own healthcare should not be 
underestimated 22. The paradigm of the clinician as the single determinant of 
clinical care is shifting to a shared decision-making process 23.  A patient who 
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is actively involved in his/her individual healthcare is more likely to have 
improved treatment compliance and better outcomes 24, 25. National health 
bodies such as the National Heath Service (NHS) in the United Kingdom (UK) 
are now promoting quantification and formal registration of the impact of 
disease via PROMs. In an initiative launched in 2009, PROMs are now being 
used to determine the impact of surgical intervention in the management of 
hernias, large joint arthritides and varicose veins 26. Work is underway to 
extend PROM usage to chronic diseases such as diabetes, asthma and 
stroke 9. The United States’ Food and Drug Administration (FDA) 
recommended the inclusion of PROMs in US clinical trials 1 and a more recent 
development is the FDA Patient Focused Drug Development Initiative. A list of 
20 diseases that are chronic, symptomatic and affect the activities of daily 
living of patients, such as heart failure, fibromyalgia and inflammatory bowel 
disease, have been designated in the initial process to be explored between 
2013 and 2015, gaining direct patient input on the impact of these diseases 
on their lives. This information will then be used by the FDA to assess 
applications for new drugs for treatment of these diseases. The patient 
narrative from this process will also be used to develop or refine PROMs 
relevant to these disease areas. Based on the results of this review, there is 
limited usage of PROMs in the oral mucosal disease literature, with oral 
medicine slowly adopting this global initiative of patient engagement.  
 
When considering levels of evidence and robustness of research, a clear goal 
is to produce high-quality randomised controlled trials, the outcomes of which 
would lend themselves to systematic review and meta-analysis for 
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comprehensive comparisons to be made between management interventions. 
Due to difficulties caused by heterogeneity of outcome measures in research, 
the COMET initiative was established in the UK in 2010 to promote the 
creation of a core outcome set for research topics. The goal of this group is to 
determine the minimum set of outcome measures that should be used in 
clinical trials, audit of clinical services and other forms of clinical research for a 
particular disease. A detailed methodology has been developed including a 
literature review to establish current outcomes used, engagement with patient 
groups to determine which outcomes they consider to be important, and then 
ultimately produce a list, ratified by both patients and clinicians, as the core 
outcome measurements for future research 27. As demonstrated from the 
heterogeneity of outcomes delineated in this review, oral medicine has yet to 
fully engage in this process. The greatest advancement in this area has been 
made in rheumatology 28, 29 although other areas of healthcare are also 
employing this process with a core outcomes group registered for head and 
neck cancer and for recurrent aphthous ulcers. Now that the heterogeneity 
has been established in OLP, RAS, OFG, MMP and PV, a forum such as the 
World Workshop on Oral Medicine could mediate the progress of core 
outcomes research in oral medicine using the results of this review as a 
foundation for engagement of both clinicians and patients and hence, the 
creation of a definitive core outcome measurement list.  
 
Although it is important to promote the use of PROMs in research and clinical 
practice, it remains essential that instruments used should be valid, reliable 
and appropriately administered. The Patient-Centered Outcomes Research 
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Institute (PCORI) is a research group authorized by the United States 
Congress to facilitate informed decision-making by patients with regard to 
their healthcare 30. Central to the work of PCORI is the promotion of robust 
methodology in PROMs, thereby ensuring ‘more valid, trustworthy and useful 
information’ 31. From the papers analysed in this review, a number of ad hoc 
instruments were used for recording burning pain 32, quality of life and 
symptom improvement, 33 while others circumvented the rigorous process of 
instrument development by changing the wording of an existing questionnaire 
for use without examining the impact of this change on the psychometrics of 
the instrument 34. The process of questionnaire development ideally involves 
patients throughout each stage from item derivation to validity and reliability 
testing 35. Using ad hoc questionnaires to record symptoms, as was done in a 
number of the studies included in this review, calls into question the 
usefulness of the information derived. The most commonly used PROM was 
VAS. Research has been conducted regarding the importance of using a 
paper version of the instrument 36, the horizontal aspect of the scale 37 and 
the caution required when photocopying the instrument 38. Authors often fail to 
stipulate the method of usage of the VAS in studies and therefore call into 
question the validity of the instrument as a PROM. The work of PCORI is 
important to provide direction not only to patients in healthcare decision-
making, but also in raising awareness of the importance of the appropriate 
use of valid and reliable PROMs. 
 
PROMs are being used as discriminators in determining the progression of 
drug management in patients with chronic disease. Current National Institute 
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for Clinical Excellence (NICE) guidance in the UK on the use of biologics in 
psoriasis state that a patient with a Dermatology Life Quality Index (DLQI) 
score of greater than 10 are eligible for biologics such as adalimumab, 
enteracept or ustekinumab 39. DLQI is one of many valid and reliable 
dermatology-specific quality of life instruments that was developed in the early 
1990s by Finlay and Khan 40. The list of PROMs generated in this review 
identifies only one oral medicine- specific quality of life instrument41, 42 which 
demonstrates the limited development and utilization to date of PROMs in oral 
medicine practice.  
 
In conclusion, the overall utility of PROMs is still limited, particularly in clinical 
trials. With engagement of allied medical disciplines in PROM usage and the 
promotion of PROMs by national healthcare bodies globally, advancement of 
PROMs is imperative for oral medicine. The World Workshop forum, along 
with the potential involvement in COMET or other such initiatives, will enable 
worldwide collaboration to promote the development and utilization of valid 
and reliable PROMs in oral medicine to improve patient care. 
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Table 1. 
Patient-reported outcome measure (PROMs) used, frequency of use and 
associated mucosal disease 
PROM Abbreviation No. of times used Disease 
Autoimmune Bullous 
Disease Quality of 
Life questionnaire 
ABQOL 1 Multi* (1) 43 
Ad hoc patient 
reported outcome 
measures 
Ad hoc 9 OLP **(7) 32, 33, 44-
48 
RAS*** (1) 49 
MMP/PV**** (1) 50 
Beck Depression 
Inventory 
BDI 4 OLP (4) 51-54 
Covi Anxiety Screen CAS 1 OLP (1) 53 
Cattell 16 Personality 
Factors 
Cattell 16PF 2 OLP (2) 53, 55 
Cornell Medical Index 
Health Questionnaire 
CMI 1 OLP (1) 47 
Chronic Oral Mucosal 
Diseases 
Questionnaire 
COMDQ 3 Multi (3) 42, 56, 57 
Clinical Scoring 
System 
CSS 9 OLP (3) 58-60 
RAS (1) 61 
MMP/PV (5) 62-66 
Dermatology Life 
Quality Index 
DLQI 2 MMP/PV (2) 67, 68 
General Health 
Questionnaire 
GHQ 5 OLP (2) 69, 70 
MMP/PV (2) 67, 68 
Multi (1) 71 
Hospital Anxiety and 
Depression  
HAD 5 OLP (1) 55 
RAS (1) 11 
MMP/PV (1) 72 
Multi (2) 73, 74 
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Hamilton Anxiety 
Scale 
HAS 1 OLP (1) 75 
Hassanyeh Rating of 
Anxiety-Depression-
Vulnerability 
Hassanyeh 
RADV 
1 OLP (1) 53 
Insitute for Personality 
and Ability Testing 
IPAT-CDQ 1 MMP/PV (1) 76 
Karolinska Scales of 
Personality 
KSP 1 OLP (1) 77 
Lipp’s Inventory of 
Stress and Symptoms 
LISS 1 OLP (1) 51 
Montgomery-Asberg 
Depression Rating 
Scale 
MADRS 1 OLP (1) 75 
Minnesota Multiphasic 
Personality Inventory 
MMPI 1 OLP (1) 78 
McGill Pain 
Questionnaire 
MPQ 2 OLP (2) 79, 80 
Numerical Rating 
Scale 
NRS 5 OLP (3) 58, 81, 82 
RAS (2) 83, 84 
Oral Health Impact 
Profile 
OHIP 19 OLP (10) 14, 34, 79, 
80, 85-90 
RAS (3) 91-93 
Multi (6) 13, 42, 71, 73, 
94, 95 
Oral Health-Related 
Quality of Life 
OHQoL 3 OLP (2) 80, 89 
Multi (1) 13 
Oral Impacts on Daily 
Performance 
OIDP 1 RAS (1) 96 
Paediatric Quality of 
Life Inventory 
PaedsQL 1 OFG (1) 97 
Paykel’s Inventory PI 1 MMP/PV (1) 98 
Profile of Mood States POMS 1 OLP (1) 99 
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Patient Satisfaction 
Questionnaire 
PSQ 1 OLP (1) 52 
Perceived Stress 
Scale 
PSS 1 OLP (1) 70 
Quick Inventory of 
Depressive 
Symptomatology 
QIDS 1 RAS (1) 100 
Raskin Depression 
Screen 
RDS 1 OLP (1) 53 
Recent Life Changes 
Questionnaire 
RLCQ 1 RAS (1) 101 
Self-rating Anxiety 
Scale 
SAS 1 RAS (1) 102 
Medical Outcomes 
Study Short Form 
SF 5 MMP/PV (2) 76, 103 
Multi (3) 71, 94, 95 
State-Trait Anxiety 
Inventory 
STAI 6 OLP (6) 12, 52-54, 104, 
105 
Visual Analogue 
Scale 
VAS 72 OLP (47) 14, 34, 58, 
60, 79, 80, 85, 86, 90, 106-
143 
RAS (19) 91, 93, 144-
161 
MMP/PV (2) 162, 
163 
Multi (4) 13, 42, 73, 
164 
Xerostomia Inventory XI 1 OLP (1) 165 
 
*Multi: multiple mucosal diseases 
**OLP: oral lichen planus 
***RAS: recurrent aphthous stomatitis 
****MMP/PV: mucous membrane pemphigoid/pemphigus vulgaris 
